bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 2 from Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Authors: Horak Christine E. , Pusztai Lajos , Xing Guan , Trifan Ovidiu C. , Saura Cristina , Tseng Ling-Ming , Chan Stephen , Welcher Rosanne , Liu David
Published: April 2023

PDF file - 94K, RNA, cRNA and GeneChip quality metrics
Supplementary Table 1 from Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Authors: Horak Christine E. , Pusztai Lajos , Xing Guan , Trifan Ovidiu C. , Saura Cristina , Tseng Ling-Ming , Chan Stephen , Welcher Rosanne , Liu David
Published: April 2023

PDF file - 77K, Baseline characteristics
Supplementary Figure 4 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Authors: Floris Giuseppe , Wozniak Agnieszka , Sciot Raf , Li Haifu , Friedman Lori , Van Looy Thomas , Wellens Jasmien , Vermaelen Peter , Deroose Christophe M. , Fletcher Jonathan A. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

PDF file - 1683K, Representative micro-PET images from GIST-PSW (A) and GIST-DFR (B) mice treated with IMA or GDC+IMA are shown. Scans were perfromed at baseline, week four (end of the treatment) and weeks six and eight - during treatment discontinuation.
Supplementary Table 1 from Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins
Authors: Travica Sandra , Pors Klaus , Loadman Paul M. , Shnyder Steven D. , Johansson Inger , Alandas Mohammed N. , Sheldrake Helen M. , Mkrtchian Souren , Patterson Laurence H. , Ingelman-Sundberg Magnus
Published: April 2023

Supplementary Table 1 - PDF file 24K, Pharmacokinetic data
Supplementary Figure 2 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Authors: Floris Giuseppe , Wozniak Agnieszka , Sciot Raf , Li Haifu , Friedman Lori , Van Looy Thomas , Wellens Jasmien , Vermaelen Peter , Deroose Christophe M. , Fletcher Jonathan A. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

PDF file - 1222K, PTEN protein expression. Strong expression of PTEN was observed in GIST-DFR (A), GIST-BOE (B), GIST882 (C) and GIST48 (D). In GIST-PSW (E) and GIST882Ly (F) the majority of the tumor cells were PTEN negative, only scattered cells showed weak cytoplasmatic staining. The endothelium of blood vessels was used as internal positive control.
Supplementary Table 1 and 2 from Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
Authors: Saenger Yvonne , Magidson Jay , Liaw Bobby , de Moll Ellen , Harcharik Sara , Fu Yichun , Wassmann Karl , Fisher David , Kirkwood John , Oh William K. , Friedlander Philip
Published: April 2023

Supplementary Table 1 and 2. Table S1 contains all of the genes tested. Table S2 describes patient selection.
Supplementary Figure 6 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification
Authors: Zheng Jianghua , Wang Jinglong , Sun Xueqing , Hao Mingang , Ding Tao , Xiong Dan , Wang Xiumin , Zhu Yu , Xiao Gang , Cheng Guangcun , Zhao Meizhong , Zhang Jian , Wang Jianhua
Published: April 2023

PDF file - 255K, CXCR7 is direct HIC1 target genes
Supplementary Figure 2 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification
Authors: Zheng Jianghua , Wang Jinglong , Sun Xueqing , Hao Mingang , Ding Tao , Xiong Dan , Wang Xiumin , Zhu Yu , Xiao Gang , Cheng Guangcun , Zhao Meizhong , Zhang Jian , Wang Jianhua
Published: April 2023

PDF file - 488K, Effects in PCa cells after knockdown of expression of HIC1
Supplementary Figure 1 from A Molecular Taxonomy for Urothelial Carcinoma
Authors: Sjödahl Gottfrid , Lauss Martin , Lövgren Kristina , Chebil Gunilla , Gudjonsson Sigurdur , Veerla Srinivas , Patschan Oliver , Aine Mattias , Fernö Mårten , Ringnér Markus , Månsson Wiking , Liedberg Fredrik , Lindgren David , Höglund Mattias
Published: April 2023

PDF file - 1.8MB, Validation of tumor clusters in external data sets
Supplementary Figure 5 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Authors: Xiang Hong , Bender Brendan C. , Reyes Arthur E. , Merchant Mark , Jumbe Nelson L. ‘Shasha’ , Romero Mally , Davancaze Teresa , Nijem Ihsan , Mai Elaine , Young Judy , Peterson Amy , Damico-Beyer Lisa A.
Published: April 2023

PDF file, 967K, Onartuzumab tumoristatic concentration range.
Supplementary Figure 4 from Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma
Authors: Levi Jelena , Kothapalli Sri-Rajashekar , Bohndiek Sarah , Yoon Joon-Kee , Dragulescu-Andrasi Anca , Nielsen Carsten , Tisma Aleksandra , Bodapati Sunil , Gowrishankar Gayatri , Yan Xinrui , Chan Carmel , Starcevic Daniela , Gambhir Sanjiv Sam
Published: April 2023

PDF file - 168K, Total and active MMP enzymes in FTC133 tumor homogenates
Supplementary Methods and Figure Legend from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
Authors: Karbach Julia , Neumann Antje , Brand Kathrin , Wahle Claudia , Siegel Ekkehard , Maeurer Markus , Ritter Erika , Tsuji Takamasa , Gnjatic Sacha , Old Lloyd J. , Ritter Gerd , Jäger Elke
Published: April 2023

PDF file, 62K.
Supplementary Figure 3 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
Authors: Karbach Julia , Neumann Antje , Brand Kathrin , Wahle Claudia , Siegel Ekkehard , Maeurer Markus , Ritter Erika , Tsuji Takamasa , Gnjatic Sacha , Old Lloyd J. , Ritter Gerd , Jäger Elke
Published: April 2023

PDF file, 86K, In-vitro activity of MBV on DC.
Supplementary Figure 5 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
Authors: Noonan Anne M. , Eisch Robin A. , Liewehr David J. , Sissung Tristan M. , Venzon David J. , Flagg Thomas P. , Haigney Mark C. , Steinberg Seth M. , Figg William D. , Piekarz Richard L. , Bates Susan E.
Published: April 2023

Supplementary Figure 5 - PDF file 60K, Changes in heart rate observed for patients in the NIH cohort during cycle 2 days 1, 8 and 15
Supplementary Figure 2 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

PDF file - 68KB, Spearman correlation of DNA methylation levels of each marker in urine sediment samples of TURBT patients.
Supplementary Figure Legend from FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System
Authors: Huang Chen , Xie Dacheng , Cui Jiujie , Li Qi , Gao Yong , Xie Keping
Published: April 2023

Supplementary Figure Legend from FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System
Supplementary Table 3 from Discovery and Prevalidation of Salivary Extracellular microRNA Biomarkers Panel for the Noninvasive Detection of Benign and Malignant Parotid Gland Tumors
Authors: Matse Johannes H. , Yoshizawa Janice , Wang Xiaoyan , Elashoff David , Bolscher Jan G.M. , Veerman Enno C.I. , Bloemena Elisabeth , Wong David T.W.
Published: April 2023

XLSX file - 22K, Average Ct and average ΔCt values from the validation phase. In the validation phase, the expression of 9 miRNAs were validated in whole saliva salmples from patients with a benign (n=19) or a malignant (n=28) parotid gland tumor.
Supplementary Table 2 from Discovery and Prevalidation of Salivary Extracellular microRNA Biomarkers Panel for the Noninvasive Detection of Benign and Malignant Parotid Gland Tumors
Authors: Matse Johannes H. , Yoshizawa Janice , Wang Xiaoyan , Elashoff David , Bolscher Jan G.M. , Veerman Enno C.I. , Bloemena Elisabeth , Wong David T.W.
Published: April 2023

XLSX file - 13K, Fold change differences and P-values of miRNA.
Supplementary Figure 2 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Authors: Yoshida Takeshi , Zhang Guolin , Smith Matthew A. , Lopez Alex S. , Bai Yun , Li Jiannong , Fang Bin , Koomen John , Rawal Bhupendra , Fisher Kate J. , Chen Ann Y. , Kitano Michiko , Morita Yume , Yamaguchi Haruka , Shibata Kiyoko , Okabe Takafumi , Okamoto Isamu , Nakagawa Kazuhiko , Haura Eric B.
Published: April 2023

PDF file - 54KB, A: Example of peak area (EIC) for EGFR pY 1172. B: Example of peak area (EIC) for MET pY 1234.
Supplementary Figure 3 from EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Authors: Bladt Friedhelm , Faden Bettina , Friese-Hamim Manja , Knuehl Christine , Wilm Claudia , Fittschen Claus , Grädler Ulrich , Meyring Michael , Dorsch Dieter , Jaehrling Frank , Pehl Ulrich , Stieber Frank , Schadt Oliver , Blaukat Andree
Published: April 2023

PDF file - 255K, Effective inhibition of in vitro tumor cell migration by EMD 1214063 and EMD 1204831. A classical "wound healing" test was performed to assess the impact of EMD 1214063 (A) and EMD 1204831 (B) on tumor cell migration. In brief, H441 lung cancer cells were seeded on day 1 (3 x 105 cells/well in 24-well plate), serum-starved on day 2, and treated on day 3 with the indicated concentrations of the EMD compounds for 1 h. After "scratching" the cell layer, cells were incubated in serum-free medium containing 100 ng/mL HGF and the indicated concentrations of the compounds for 24h. Controls were untreated cells with (left) or without HGF (right). At 0 h and 24 h, cells were washed, fixed with ice-cold methanol, and stained with crystal violet (0.05% in 50% ethanol). Treatment with EMD 1214063 or EMD 1204831 resulted in a strong inhibition of tumor cell migration, preventing wound healing. Pictures were taken at 5x magnification. Data are representative of two independent experiments.
Supplementary Table 2 from ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer
Authors: Kabbout Mohamed , Garcia Melinda M. , Fujimoto Junya , Liu Diane D. , Woods Denise , Chow Chi-Wan , Mendoza Gabriela , Momin Amin A. , James Brian P. , Solis Luisa , Behrens Carmen , Lee J. Jack , Wistuba Ignacio I. , Kadara Humam
Published: April 2023

Supplementary Table 2 - XLSX file 92K, Gene features significantly differentially expressed in lung cancer cells transfected with ETS2-specific siRNA compared to cells transfected with control siRNA
Supplementary Methods from Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Authors: Oxnard Geoffrey R. , Paweletz Cloud P. , Kuang Yanan , Mach Stacy L. , O'Connell Allison , Messineo Melissa M. , Luke Jason J. , Butaney Mohit , Kirschmeier Paul , Jackman David M. , Jänne Pasi A.
Published: April 2023

PDF file - 91K
Supplementary Table 1 from EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma
Authors: Liu Lei , Wang Weijuan , Chen Hui , Zhao Yan , Bai Wei , Yin Zhanxin , He Chuangye , Jia Jia , Yang Man , Xia Jielai , Fan Daiming , Han Guohong
Published: April 2023

PDF file - 40K, Supplementary Table 1. Overall response Determined with Evaluation of Target, Nontarget, and New Lesions.
Supplementary Tables 1 - 2, Figures 1 - 4 from Survival Signals and Targets for Therapy in Breast Implant–Associated ALK− Anaplastic Large Cell Lymphoma
Authors: Lechner Melissa G. , Megiel Carolina , Church Connor H. , Angell Trevor E. , Russell Sarah M. , Sevell Rikki B. , Jang Julie K. , Brody Garry S. , Epstein Alan L.
Published: April 2023

PDF file, 5811K, Supplemental Table 1. Antibody clones used for flow cytometry, immunocytochemistry, and western blotting studies. Supplemental Table 2. Phenotype analysis of TLBR cell lines by flow cytometry. Supplemental Figure 1. Cytogenetic analyses of TLBR cell lines. Supplemental Figure 2. Immunocytochemistry of TLBR cell lines. Supplemental Figure 3. Sensitivity of TLBR cell lines to 5-aza-2'-deoxycytidine (AZA). Supplemental Figure 4. Notch signaling in TLBR cell lines.
Supplementary Figure 1 from Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer
Authors: Liu Hanqing , Xiao Fang , Serebriiskii Ilya G. , O'Brien Shane W. , Maglaty Marisa A. , Astsaturov Igor , Litwin Samuel , Martin Lainie P. , Proia David A. , Golemis Erica A. , Connolly Denise C.
Published: April 2023

PDF file - 78KB, Drug sensitization summary for HCT116 cells.
Supplementary Figure 1 from GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer
Authors: Nebiker Christian A. , Han Junyi , Eppenberger-Castori Serenella , Iezzi Giandomenica , Hirt Christian , Amicarella Francesca , Cremonesi Eleonora , Huber Xaver , Padovan Elisabetta , Angrisani Basilio , Droeser Raoul A. , Rosso Raffaele , Bolli Martin , Oertli Daniel , von Holzen Urs , Adamina Michel , Muraro Manuele G. , Mengus Chantal , Zajac Paul , Sconocchia Giuseppe , Zuber Markus , Tornillo Luigi , Terracciano Luigi , Spagnoli Giulio C.
Published: April 2023

PDF - 216K, Notch Box plot of histoscore values in CRC TMA upon staining with GM-CSF and M-CSF specific reagents.
Supplementary Tables 1 - 6 from Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival
Authors: Hu Caroline Y. , Mohtat Davoud , Yu Yiting , Ko Yi-An , Shenoy Niraj , Bhattacharya Sanchari , Izquierdo Maria C. , Park Ae Seo Deok , Giricz Orsolya , Vallumsetla Nishanth , Gundabolu Krishna , Ware Kristin , Bhagat Tushar D. , Suzuki Masako , Pullman James , Liu X. Shirley , Greally John M. , Susztak Katalin , Verma Amit
Published: April 2023

PDF file - 77K, Supplementary Table 1: Clinical and Pathological characteristics of tumor samples. Supplementary Table 2: Aberrantly methylated and underexpressed loci with overlapping enhancer (H3K4me1) marks. Supplementary Table 3: Transcription factor binding sites enriched in differentially methylated regions in RCC. Supplementary Table 4: List of Gene and Pathways hypermethylated and underexpressed in RCC. Supplementary Table 5: Genes deleted in RCC. Supplementary Table 6: Genes amplified in RCC.
Supplementary Figure Legend from Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Authors: Khalili Jahan S. , Liu Shujuan , Rodríguez-Cruz Tania G. , Whittington Mayra , Wardell Seth , Liu Chengwen , Zhang Minying , Cooper Zachary A. , Frederick Dennie T. , Li Yufeng , Zhang Min , Joseph Richard W. , Bernatchez Chantale , Ekmekcioglu Suhendan , Grimm Elizabeth , Radvanyi Laszlo G. , Davis Richard E. , Davies Michael A. , Wargo Jennifer A. , Hwu Patrick , Lizée Gregory
Published: April 2023

PDF file, 94K.
Supplementary Figure 5 from Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Authors: Khalili Jahan S. , Liu Shujuan , Rodríguez-Cruz Tania G. , Whittington Mayra , Wardell Seth , Liu Chengwen , Zhang Minying , Cooper Zachary A. , Frederick Dennie T. , Li Yufeng , Zhang Min , Joseph Richard W. , Bernatchez Chantale , Ekmekcioglu Suhendan , Grimm Elizabeth , Radvanyi Laszlo G. , Davis Richard E. , Davies Michael A. , Wargo Jennifer A. , Hwu Patrick , Lizée Gregory
Published: April 2023

PDF file, 78K, (A) Dose titration curve showing surface expression of PD-L1 on TAFs as measured by flow cytometry 18 hours following exposure to titrated doses of IL-1α or IL-1β. (B) Time course experiment assessing surface expression of PD-L1 by flow cytometry following exposure of TAFs to 1 ng/ml IL-1β.
Supplementary Figure 5 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Authors: Matas-Céspedes Alba , Rodriguez Vanina , Kalko Susana G. , Vidal-Crespo Anna , Rosich Laia , Casserras Teresa , Balsas Patricia , Villamor Neus , Giné Eva , Campo Elías , Roué Gaël , López-Guillermo Armando , Colomer Dolors , Pérez-Galán Patricia
Published: April 2023

PDF file - 234K, BKM120 shows anti-proliferative properties.
Supplementary Figure 1 from Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Authors: Khalili Jahan S. , Liu Shujuan , Rodríguez-Cruz Tania G. , Whittington Mayra , Wardell Seth , Liu Chengwen , Zhang Minying , Cooper Zachary A. , Frederick Dennie T. , Li Yufeng , Zhang Min , Joseph Richard W. , Bernatchez Chantale , Ekmekcioglu Suhendan , Grimm Elizabeth , Radvanyi Laszlo G. , Davis Richard E. , Davies Michael A. , Wargo Jennifer A. , Hwu Patrick , Lizée Gregory
Published: April 2023

PDF file, 473K, (A) Frequencies of IL-1α and IL-1β staining at different disease stages. Sections of a melanoma progression tissue array stained with antibodies specific for IL-1α or IL-1β and visualized by Vector-red immunostaining. Red color indicates positive staining for (C-E) IL-1α or (G-I) IL-1β in representative primary and metastatic tumors. (J) IL-1α or (K) IL-1β from stage 3 lymph node metastasis of tumors with (red) or without (black) the BRAF V600E mutation. Scores indicates the product of the intensity of signal (0-3) and frequency (0-100) of immunoreactive cells. (L) Presence or absence of IL-1α or IL-1β in melanoma cell lines with known BRAF mutational status. Asterisks, in house, or references (ref.) indicate the source of mutational analysis, (first) and the source of the IL-1 analysis (first and last respectively). Methods of BRAF mutational analysis are indicated by P, pyrosequencing; S, Sanger sequencing; Q, sequenome. Bold text indicates cell lines used in this study.
Supplemental Figure S5 and Figure S6 from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Authors: Hoffman-Luca C. Gianna , Ziazadeh Daniel , McEachern Donna , Zhao Yujun , Sun Wei , Debussche Laurent , Wang Shaomeng
Published: April 2023

Supplemental Figure S5 and Figure S6. Figure S5. Testing the role of BAX and BAK for the activity of ABT-263 or SAR in MV4;11 cells. Figure S6. Evaluation of the role of p53 for the activity of SAR and ABT-263 in the MV4;11 cell line.
Supplementary Table 2 from MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis
Authors: Tong Joanna H. , Yeung Sai F. , Chan Anthony W.H. , Chung Lau Y. , Chau Shuk L. , Lung Raymond Wai Ming , Tong Carol Y. , Chow Chit , Tin Edith K.Y. , Yu Yau H. , Li Hui , Pan Yi , Chak Wing P. , Ng Calvin S.H. , Mok Tony S.K. , To Ka F.
Published: April 2023

Summary for the histopathological characteristics, clinical information of patients with METâˆ†14 mutations
Supplementary Tables S1-S3 and S5 from Identification and Functional Validation of Reciprocal microRNA–mRNA Pairings in African American Prostate Cancer Disparities
Authors: Wang Bi-Dar , Ceniccola Kristin , Yang Qi , Andrawis Ramez , Patel Vyomesh , Ji Youngmi , Rhim Johng , Olender Jacqueline , Popratiloff Anastas , Latham Patricia , Lai Yinglei , Patierno Steven R. , Lee Norman H.
Published: April 2023

Supplementary Tables S1-S3 and S5. Supplementary Tables S1 for the clinical characteristics of the tissue samples used in (A) microarray, (B)qRT-PCR and (C)IHC assays. Table S2 and S3 describe the primer sequences for mRNA and miRNA validations. Table S5 describes A) AA-enriched/depleted, B)AA-specific, C) EA-specific and D)PCa-associated miRNAs.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplementary Data from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Supplementary Tables and Supplementary Materials and Methods
Supplementary Materials, Methods & Table S1 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Materials, Methods & Table S1. Supplementary Materials & Methods: Generation & characterization of the LMD-PSMA cells, YC-27 synthesis, primers for mPSMA PCR, and determining the limit of detection of YC-27. Supplementary Table S1: Residual tumor post surgery as determined by imaging and palpation. Author contributions & Competing interests.
Supplementary Figures S3-S6 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Figures S3-S6. S3. PSMA expression in LMD-PSMA cells. S4. PSMA expression has no effect on cell growth. S5. Cell migration is similar between LMD and LMD-PSMA cells. S6. LMD and LMD-PSMA cells both are capable of forming xenografts.
Supplemental Tables, Figures and Legends from Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer
Authors: Yun Eun-Jin , Zhou Jiancheng , Lin Chun-Jung , Hernandez Elizabeth , Fazli Ladan , Gleave Martin , Hsieh Jer-Tsong
Published: April 2023

Table S1. Primers for quantitative RT-PCR. Table S2. The list of primers for ChIP detection; CD44 promoter region. Figure S1. Loss of DAB2IP increased clonogenicity and stemness in normal prostate epithelial cells. Figure S2. Loss of DAB2IP increased in vitro invasion and motility in normal prostate epithelial cells. Figure S3. DAB2IP inhibits CD44 expression in human prostate epithelial cell lines. Figure S4. Wnt pathway correlates with CRPC progression. Figure S5. AR inhibitor doesn't affect the expression of CD44. Figure S6. All CD44 variants respond to Wnt inhibitor. Figure S7. Wnt signal regulates CD44 expression and stem cell properties. Figure S8. Wnt signal pathway mediates the expression of CD44. Figure S9. Wnt inhibitors diminish the chemo-resistance of KD cells. Figure S10. Overexpression of CD44 rescues the growth inhibition by LGK974. Figure S11. Synergistic effect of Wnt inhibitors combined with docetaxel on Du145 cells.
Data Supplement from CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplementary Table 1 - Gender/tumor characteristics, radiologic response, follow-up, and survival.
Data Supplement from CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplementary Figure 2 - Single cell assay of gastric cancer cell lines.
Data Supplement from CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplementary Figure 4 - Invasion and soft agar assays of gastric cancer monolayer cells and spheroid cells.
Data Supplement from CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Authors: Yoon Changhwan , Park Do Joong , Schmidt Benjamin , Thomas Nicholas J. , Lee Hae-June , Kim Teresa S. , Janjigian Yelena Y. , Cohen Deirdre J. , Yoon Sam S.
Published: April 2023

Supplementary Figure 5 - Cisplatin chemotherapy combined with Hedgehog pathway inhibition with vismodegib in MKN-45 xenografts.
Supplementary Figure S1 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

Unsupervised HCL of an external dataset of breast cancer metastases (GSE14018) using the 358 "breast cancer liver metastasis-selective genes" derived from SAM analyses of metastases in the test dataset.
supplemental figure legend from Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
Authors: Rothenberg S. Michael , McFadden David G. , Palmer Edwin L. , Daniels Gilbert H. , Wirth Lori J.
Published: April 2023

supplemental figure legend
Supplementary Table 1 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Authors: Zegers Catharina M.L. , Rekers Nicolle H. , Quaden Dana H.F. , Lieuwes Natasja G. , Yaromina Ala , Germeraad Wilfred T.V. , Wieten Lotte , Biessen Erik A.L. , Boon Louis , Neri Dario , Troost Esther G.C. , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary Table 1. Results of flowcytometric analysis
Supplementary Figure 1 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Authors: Zegers Catharina M.L. , Rekers Nicolle H. , Quaden Dana H.F. , Lieuwes Natasja G. , Yaromina Ala , Germeraad Wilfred T.V. , Wieten Lotte , Biessen Erik A.L. , Boon Louis , Neri Dario , Troost Esther G.C. , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary Figure 1. Treatment schedules used in in-vivo experiments.
Supplementary Table 3 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Tarlock Katherine , Alonzo Todd A. , Gerbing Robert B. , Raimondi Susana C. , Hirsch Betsy A. , Sung Lillian , Pollard Jessica A. , Aplenc Richard , Loken Michael R. , Gamis Alan S. , Meshinchi Soheil
Published: April 2023

Time to absolute neutrophil count (ANC) and platelet recovery for FLT3/ITD patients in the No-GO and GO cohorts treated on AAML0531.
Supplementary Figures from Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer
Authors: Sanz-Pamplona Rebeca , Lopez-Doriga Adriana , Paré-Brunet Laia , Lázaro Kira , Bellido Fernando , Alonso M. Henar , Aussó Susanna , Guinó Elisabet , Beltrán Sergi , Castro-Giner Francesc , Gut Marta , Sanjuan Xavier , Closa Adria , Cordero David , Morón-Duran Francisco D. , Soriano Antonio , Salazar Ramón , Valle Laura , Moreno Victor
Published: April 2023

Supplementary Figures (1 to 15)
Data Supplement from Complex Disease–, Gene–, and Drug–Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics
Authors: Li Jing , Kim Seongho , Sha Xianyi , Wiegand Richard , Wu Jianmei , LoRusso Patricia
Published: April 2023

Supplementary Table 1. PBPK model-predicted veliparib plasma pharmacokinetic (PK) parameters and mechanistic kidney model parameters under different scenarios. Supplementary Figure S1. In vitro metabolism of veliparib. The disappearance of veliparib (A) and formation of M8 (B) when veliparib (100 micromol/L) was incubated with recombinant human CYP1A1, 1A2, 2C9, 2C19, 2D6, 3A4, and 3A5 SupersomesTM at CYP concentrations of 10 to 160 pmol/mL. The negative control was the incubation with insect cell control SupersomesTM. The points are the average of duplicate determination (with coefficient variation <10%). Supplementary Figure S2. Goodness-of-fit plots for the final parent-metabolite population pharmacokinetic model. Supplementary Figure S3. Sensitivity analysis showing the impact of ABCB1 activity (intrinsic efflux clearance) on veliparib plasma pharmacokinetic parameters and mechanistic kidney model parameters. Sensitivity analysis was performed with ABCB1 intrinsic efflux clearance varying from 0.1 to 3 microl/min/106 cells while OCT2 intrinsic uptake clearance fixing at 8.59 microl/min/106 cells.
Supplementary Figure Legends from Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma
Authors: O'Leary Brianne R. , Fath Melissa A. , Bellizzi Andrew M. , Hrabe Jennifer E. , Button Anna M. , Allen Bryan G. , Case Adam J. , Altekruse Sean , Wagner Brett A. , Buettner Garry R. , Lynch Charles F. , Hernandez Brenda Y. , Cozen Wendy , Beardsley Robert A. , Keene Jeffery , Henry Michael D. , Domann Frederick E. , Spitz Douglas R. , Mezhir James J.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 2 from Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer
Authors: Li Tuan-Jie , Jiang Yu-Ming , Hu Yan-Feng , Huang Lei , Yu Jiang , Zhao Li-Ying , Deng Hai-Jun , Mou Ting-Yu , Liu Hao , Yang Yang , Zhang Qi , Li Guo-Xin
Published: April 2023

Association of CD66b+ and MMP-9+ cells in the invasive margin of GC (n = 245).
Supplementary methods and legends from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

Supplementary Methods and legends for Supplementary tables and figures
Supplementary Figure Legend from Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Authors: Hijioka Susumu , Hosoda Waki , Matsuo Keitaro , Ueno Makoto , Furukawa Masayuki , Yoshitomi Hideyuki , Kobayashi Noritoshi , Ikeda Masafumi , Ito Tetsuhide , Nakamori Shoji , Ishii Hiroshi , Kodama Yuzo , Morizane Chigusa , Okusaka Takuji , Yanagimoto Hiroaki , Notohara Kenji , Taguchi Hiroki , Kitano Masayuki , Yane Kei , Maguchi Hiroyuki , Tsuchiya Yoshiaki , Komoto Izumi , Tanaka Hiroki , Tsuji Akihito , Hashigo Syunpei , Kawaguchi Yoshiaki , Mine Tetsuya , Kanno Atsushi , Murohisa Go , Miyabe Katsuyuki , Takagi Tadayuki , Matayoshi Nobutaka , Yoshida Tsukasa , Hara Kazuo , Imamura Masayuki , Furuse Junji , Yatabe Yasushi , Mizuno Nobumasa
Published: April 2023

Supplementary Figure Legend
Supplementary figure legends from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

Supplementary figure legends
Figure S5 from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

AZD1208 and quizartinib co-treatment was well tolerated in the orthotopic model.
Supplementary Figure S5 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

Differential expression of immune markers AMCs in patients with benign tumours and EOCs in the discovery set. The percentage of monocytes and lymphocytes (and their subsets) in ascites that expressed PD-1, PD-L1 and CD69 was determined. Analysis of PD-L1+ CD11c+ cells was omitted due to missing data points. Statistical analysis was performed using the Mann-Whitney U test.
Supplementary Figure S4 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

Differential expression of immune markers on PBMCs in patients with benign tumours and high grade serous (HGS) tumours in the discovery and validation cohorts. A: The percentage of monocytes and lymphocytes (and their subsets) in PBMCs from patients with benign tumours or HGS that expressed PD-1, PD-L1 and CD69 in the discovery set. B: Differential expression of PBMC markers between benign tumours and HGS in the validation set.
Supp Fig S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

p53 immunohistochemistry in radical prostatectomy sample detects p.R282W mutation. Note that this mutations was missed in a separate, poorly preserved tumor sample (see Supp Fig S1). Reduced from 200x magnification.
Evaluation of added discriminatory ability from A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
Authors: Terry Kathryn L. , Schock Helena , Fortner Renée T. , Hüsing Anika , Fichorova Raina N. , Yamamoto Hidemi S. , Vitonis Allison F. , Johnson Theron , Overvad Kim , Tjønneland Anne , Boutron-Ruault Marie-Christine , Mesrine Sylvie , Severi Gianluca , Dossus Laure , Rinaldi Sabina , Boeing Heiner , Benetou Vassiliki , Lagiou Pagona , Trichopoulou Antonia , Krogh Vittorio , Kuhn Elisabetta , Panico Salvatore , Bueno-de-Mesquita H. Bas , Onland-Moret N. Charlotte , Peeters Petra H. , Gram Inger Torhild , Weiderpass Elisabete , Duell Eric J. , Sanchez Maria-Jose , Ardanaz Eva , Etxezarreta Nerea , Navarro Carmen , Idahl Annika , Lundin Eva , Jirström Karin , Manjer Jonas , Wareham Nicholas J. , Khaw Kay-Tee , Byrne Karl Smith , Travis Ruth C. , Gunter Marc J. , Merritt Melissa A. , Riboli Elio , Cramer Daniel W. , Kaaks Rudolf
Published: April 2023

Evaluation of added discriminatory ability of each biomarker using Net Reclassification Improvement (NRI)
Supplemental Table 3 from Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Authors: Kawai Takayuki , Yasuchika Kentaro , Seo Satoru , Higashi Tatsuya , Ishii Takamichi , Miyauchi Yuya , Kojima Hidenobu , Yamaoka Ryoya , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Nakamoto Yuji , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Univariate analysis with respect to outcome.
Supplementary Table S5 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

Proportion of variance in WFS1 expression explained by genetic effects in 11 relevant GTEx tissues.
Supplemental Figure 2 from Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
Authors: Kawai Takayuki , Yasuchika Kentaro , Seo Satoru , Higashi Tatsuya , Ishii Takamichi , Miyauchi Yuya , Kojima Hidenobu , Yamaoka Ryoya , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Nakamoto Yuji , Hatano Etsuro , Uemoto Shinji
Published: April 2023

EGFP-marking of the K19+ cells in human HCC cell lines.
Supplementary Table S2 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

The Platinum Study CAO GWAS results for SNPs in Mendelian deafness genes.
Supplementary Table S1 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

Demographic features and clinical characteristics of 511 genetically European male germ cell tumor (GCT) survivors at the time of audiometry.
Table S1 from Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells
Authors: Paolillo Carmela , Mu Zhaomei , Rossi Giovanna , Schiewer Matthew J. , Nguyen Thomas , Austin Laura , Capoluongo Ettore , Knudsen Karen , Cristofanilli Massimo , Fortina Paolo
Published: April 2023

Primer list
Supplementary Figure S1 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

Principal component analysis of The Platinum Study cohort.
Supplementary Table 6 from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

All nonsynonymous mutations detected in WES samples
Supplementary Table 5 from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

List of genes in signature of disruption along with disruption scores for functional adenomas
Supplementary Table 4 from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

Arm-level SCNAs from paired or imputed copy number data
Supplementary Fig 1 from Landscape of Genomic Alterations in Pituitary Adenomas
Authors: Bi Wenya Linda , Horowitz Peleg , Greenwald Noah F. , Abedalthagafi Malak , Agarwalla Pankaj K. , Gibson Wiliam J. , Mei Yu , Schumacher Steven E. , Ben-David Uri , Chevalier Aaron , Carter Scott , Tiao Grace , Brastianos Priscilla K. , Ligon Azra H. , Ducar Matthew , MacConaill Laura , Laws Edward R. , Santagata Sandro , Beroukhim Rameen , Dunn Ian F.
Published: April 2023

Imputed copy-number profiles from expression data
Supplemental Figure 2 from The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
Authors: Salomon Matthew P. , Wang Xiaowen , Marzese Diego M. , Hsu Sandy C. , Nelson Nellie , Zhang Xin , Matsuba Chikako , Takasumi Yuki , Ballesteros-Merino Carmen , Fox Bernard A. , Barkhoudarian Garni , Kelly Daniel F. , Hoon Dave S.B.
Published: April 2023

PCA analysis of genome-wide gene expression profiles. PCA analysis using all genes in the gene expression data set. Points are colored by the percent of the genome altered by SCNAs. The three PA subtypes are indicated by the shape of the points, with GH-secreting PAs represented by dots, ACTH-secreting PAs represented by triangles, and endocrine-inactive PAs represented by squares. Ellipses indicate 95% confidence intervals. Overall, PAs cluster by PA subtype and not by the percent of the genome disrupted by SCNAs.
Supplementary Information from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Authors: Dorneburg Carmen , Fischer Matthias , Barth Thomas F.E. , Mueller-Klieser Wolfgang , Hero Barbara , Gecht Judith , Carter Daniel R. , de Preter Katleen , Mayer Benjamin , Christner Lisa , Speleman Frank , Marshall Glenn M. , Debatin Klaus-Michael , Beltinger Christian
Published: April 2023

Supplementary Material and Methods
Figure S3 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

PDE4B CRISPR KO
Figure S2 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
Authors: Cooney Jeffrey D. , Lin An-Ping , Jiang Daifeng , Wang Long , Suhasini Avvaru N. , Myers Jamie , Qiu ZhiJun , Wölfler Albert , Sill Heinz , Aguiar Ricardo C.T.
Published: April 2023

Cell viability
Figure S3 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

Pathways associated with high or low ISG expression levels in breast cancer patients
Figure S2 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

Representative images showing MCF-7 cells with 'low', 'medium' and 'high' amounts of BrdU foci.
Figure S1 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

Resistant phenotypes and increased expression levels of ISGs in MCF-7 cells that were independently cultured to tamoxifen resistance and radioresistance.
Supplementary Tables from Recurrent TRIO Fusion in Nontranslocation–Related Sarcomas
Authors: Delespaul Lucile , Lesluyes Tom , Pérot Gaëlle , Brulard Céline , Lartigue Lydia , Baud Jessica , Lagarde Pauline , Le Guellec Sophie , Neuville Agnès , Terrier Philippe , Vince-Ranchère Dominique , Schmidt Susanne , Debant Anne , Coindre Jean-Michel , Chibon Frédéric
Published: April 2023

Supplementary Table 1: RT-PCR primers used for fusion transcripts detection. Supplementary Table 2: Primers used for fusion transcript quantification. Supplementary Table 3: shRNA sequences.Supplementary Table 4: Sarcomas cohort analysed in aCGH (n=24).Supplementary Table 5: 69 differentially overexpressed genes in six fused TRIO samples versus 111 non-fused TRIO samples. Supplementary Table 6: 354 differentially underexpressed genes in six fused TRIO samples versus 111 non-fused TRIO samples.